Clinical trials: Psychiatric Disorders
Non 24 Hour Sleep Wake Disorder
Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception
The purpose of this study is to evaluate the safety of a one year open-label treatment of tasimelteon in male and female subjects with Non-24-Hour Sleep-Wake Disorder.
- Trial name
- NCT01218789
- Testing
- tasimelteon
- Where
- 7 sites in France
- Volunteers
- 140 people
- Sponsor
- Vanda Pharmaceuticals
Monitoring, Physiologic, Vital Signs
Bodytrak® Feasibility Study
Bodytrak® is a wireless earpiece which can monitor the user's vital signs such as tympanic (ear) temperature and heart rate. The earpiece is non-invasive and should fit comfortably within the right ear, similar to an earphone…
- Conditions
- Monitoring, Physiologic, Vital Signs, Sepsis, Altered Level of Consciousness
- Trial name
- NCT03139955
- Testing
- Bodytrak
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Inova Design Solutions Ltd
Anxiety Disorder, Anxiety Disorders
Study Of Generalized Anxiety Disorder
This study is designed to evaluate the efficacy and safety in Generalized Anxiety Disorder patients
- Trial name
- NCT00135525
- Testing
- Paroxetine
- Sponsor
- GlaxoSmithKline
Mild Cognitive Impairment, Alzheimer Disease
Alzheimer's and Blood Glucose Levels
The Alzheimer's and Blood Glucose Levels Study is researching the differences in blood glucose levels between people with and without Mild Cognitive Impairment or Alzheimer's disease with the aim of early detection of Alzheimer's…
- Trial name
- NCT04614376
- Where
- Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bio Conscious Technologies Inc.
Anxiety Disorders, Major Depressive Disorder
Acquisition and Analysis of Relationships Between Longitudinal Emotional Signals Produced by an Artificial Intelligence Algorithm and Self-questionnaires Used in the Psychiatric Follow-up of Patients With Mood and/or Anxiety Disorders: a Real-Environment Study.
The worldwide prevalence of anxiety and depression increased massively during the pandemic, with a 25% rise in the number of patients suffering from psychological distress.
- Trial name
- EMOACQ-1 (NCT05988840)
- Testing
- Acquisition and analysis of relationships between Longitudinal Emotional Signals produced by a software and Self-questionnaires.
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Emobot
Alzheimer Disease
A Clinical Study to Evaluate the Long-Term Safety Sodium Oligomannate Capsules (GV-971)
A clinical study to evaluate the long-term safety of Sodium Oligomannate Capsules (GV-971)
- Trial name
- NCT05058040
- Testing
- Sodium Oligomannate Capsules
- Where
- 63 sites in China
- Volunteers
- 2,500 people
- Sponsor
- Green Valley (Shanghai) Pharmaceuticals Co., Ltd.
Bipolar Disorder, Elderly
Long-term Study of FK949E in Elderly Bipolar Disorder Patients
FK949E was administered to elderly bipolar disorder patients with major depressive episode for 52 weeks. Its safety, efficacy, and plasma concentration change were evaluated in an open-label manner.
- Trial name
- NCT01737268
- Testing
- FK949E
- Where
- 32 sites in Japan
- Volunteers
- 20 people
- Sponsor
- Astellas Pharma Inc
Erectile Dysfunction
Clinical Proof-of-concept Study for the Combination BAY60-4552 / Vardenafil for the Treatment of Erectile Dysfunction Not Sufficiently Responsive to Standard Therapy With PDE5 Inhibitors
This study examines the efficacy and safety of the combination treatment BAY60-4552 plus vardenafil in patients with erectile dysfunction, who do not sufficiently respond to therapy with PDE5 (Phosphodiesterase 5) inhibitors.
- Trial name
- NCT01168817
- Testing
- BAY60-4552 plus Vardenafil, Vardenafil
- Where
- 36 sites in Finland, France and 5 more
- Volunteers
- 140 people
- Sponsor
- Bayer
Postpartum Depression
A Study of BRII-297 in Healthy Adult Subjects
The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetics of BRII-297 in healthy adult subjects.
- Trial name
- NCT05845840
- Testing
- BRII-297
- Where
- Australia
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Brii Biosciences Limited
Depressive Disorder, Major
Study Evaluating the Efficacy and Safety of Desvenlafaxine Tablets in Adult Outpatients With Major Depressive Disorder
The primary objective is to compare the antidepressant efficacy, safety, and tolerability of DVS SR versus placebo in subjects with Major Depressive Disorder.
- Trial name
- NCT00300378
- Testing
- desvenlafaxine 50 mg, desvenlafaxine 100 mg
- Where
- 43 sites in Croatia, Estonia and 8 more
- Volunteers
- 480 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Trichotillomania
Technology Assisted Treatment of Trichotillomania: Open Trial
This open-label feasibility trial evaluates the use of the Keen2 awareness bracelet for adults with trichotillomania (hair-pulling disorder). Participants will use the bracelet for eight weeks.
- Trial name
- NCT07224126
- Testing
- Keen2 Predictive Awareness Bracelet
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- HabitAware Inc.
PTSD
Study Comparing Two Versus Three Active MDMA-assisted Sessions in U.S. Military Veterans With Chronic PTSD
The goal of this clinical trial is to learn if MDMA-assisted therapy is effective in U.S. military veterans with at least moderate chronic PTSD.
- Trial name
- MPVA6 (NCT04784143)
- Testing
- Midomafetamine, Psychotherapy
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Resilient Pharmaceuticals
Bipolar Disorder, Depression, Bipolar
Safety and Efficacy Trial of the Use of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Patients With Bipolar Depression
The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.
- Trial name
- NCT00060489
- Testing
- SEROQUEL (quetiapine fumarate) Tablets
- Where
- 27 sites in United States
- Sponsor
- AstraZeneca
Insomnia Disorders
A Study to Determine the Abuse Potential of Single Oral Doses of Lemborexant Compared to Zolpidem, Suvorexant and Placebo in Healthy, Non-Dependent, Recreational Sedative Users
The primary purpose of this study is to evaluate the abuse potential of lemborexant (E2006) in comparison to placebo and 2 controls with known abuse potential (ie, zolpidem and suvorexant) with similar indications (zolpidem and…
- Trial name
- NCT03158025
- Testing
- Zolpidem tablets, Suvorexant tablets, over-encapsulated, Lemborexant tablets
- Where
- Canada
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Alzheimer Disease
A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of JNJ-54861911 in patients with prodromal Alzheimer's disease (pAD).
- Trial name
- NCT01978548
- Testing
- JNJ-54861911 10 mg, JNJ-54861911 50 mg
- Where
- 10 sites in Belgium, Netherlands and 2 more
- Volunteers
- 45 people
- Sponsor
- Janssen Research & Development, LLC
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
Assessing Clinical Outcomes in Alzheimer's Disease Agitation
This is a multi-center, double-blind, placebo-controlled, randomized withdrawal study to evaluate the efficacy and safety of AXS-05 compared to placebo in the treatment of agitation symptoms in subjects with agitation associated…
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation,Psychomotor
- Trial name
- ACCORD (NCT04797715)
- Testing
- AXS-05
- Where
- 63 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- Axsome Therapeutics, Inc.
Major Depressive Disorder
Study of the Efficacy and Safety of LY2940094 in Participants With Major Depressive Disorder (MDD)
This study will determine the efficacy, safety, and tolerability of a 40 milligrams (mg) once-daily (QD) dose of LY2940094 for 8 weeks in participants with MDD.
- Trial name
- NCT01724112
- Testing
- LY2940094
- Where
- 10 sites in United States
- Volunteers
- 136 people
- Sponsor
- BlackThorn Therapeutics, Inc.
Anxiety Disorder
Understanding Patient Engagement Trends in Anxiety Disorder Clinical Research
Clinical trials, specifically focused on anxiety disorder, are crucial in assessing the safety and efficacy of new treatments. These trials serve as fundamental instruments in determining whether emerging medications outperform…
- Trial name
- NCT06155565
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Cognitive Deficits, Alzheimer Disease
Acupuncture Treatment for Improving Alzheimer's Dementia
Evaluate cognitive improvement pre amd post acupuncture treatment in patients with probable alzheimer's dementia as measured by MOCA score and also per form A( measure of patient's personal information). Also caregiver input.
- Trial name
- NCT04064021
- Testing
- Acupunture
- Sponsor
- N & S Neurology Center, A Medical Group, Inc
Alzheimer's Disease
A Study of Gantenerumab in Participants With Prodromal Alzheimer's Disease
This multi-center, randomized, double-blind, placebo-controlled parallel-group study will evaluate the effect of gantenerumab (RO4909832) on cognition and functioning and the safety and pharmacokinetics in participants with…
- Trial name
- Scarlet Road (NCT01224106)
- Testing
- Gantenerumab
- Where
- 139 sites in United States, Argentina and 22 more
- Volunteers
- 799 people
- Sponsor
- Hoffmann-La Roche